Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RAFA's future looks bleak !!!!!!!!!!!!!!!!!!!!!!!!!!!
IB_ :(
Is RAFA just another scam stock !!!!!!!!!!!!!!!!!!!!!!!
LoL LoL,
IB_
And it's the other stock of someone's life!!! ??
Their 'audit' can say anything it wants. It's OTC and the only people who review the audit work/own RAFA. Stock in Pred 2.0.
It could be lies, lies, lies. After all we are dealing with a Russian here that would never be prosecuted
Ridiculous to even say that. there is nothing similar between those two companies. Cash cash cash
This is like PRED. The company doesn't care about its shareholders. They are still doing the audit that lasts forever. One has to wonder the validity of the numbers published and reported to OTC markets.
Agreed. There is a Twitter account (likely owned/run by ???) and a YouTube channel where Ilya posts videos from time to time.
I have called that # several times and talked to the PR rep. For 3 yrs he has shared the same messages that have been published.
I've emailed with no response. This company doesn't care about it's investors as we watch our investment deep dive. No words from the CEO on uplisting, or when the new audit we must wait for is expected to be completed.
Has anyone tried to call the company? No one answers. How is that possible.
Pulled from their last PR.
For more information contact:
RAFARMA (307) 429-2029
RAFA mgt was in New York two weeks ago giving a presentation. Where any of you here at the presentation?
Why would you call a company that did $51 million in revenue and made $18 million in gross profit in the first 3 quarters of 2021 a bust? It seems to be the opposite.
RAFA getting a nice spike today !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Be Careful,
IB_ ;)
$RAFA RAFA Enters into Negotiations with JINR for Ultra-Cutting Edge Nuclear Research
Press Release | 12/21/2021
Nicosia, Cyprus, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is currently negotiating with the Joint Institute for Nuclear Research (JINR), an international intergovernmental scientific organization established by eleven founding countries in 1956 and registered by the United Nations. The purpose of the current negotiations is the development and implementation of Rafarma Pharmaceuticals’ projects related to nuclear medicine technologies, radiopharmaceuticals, radiotherapy and promising projects in related industries. Currently, our company produces devices for nuclear medicine, such as microspheres with Yttrium-90, micro sources based on Iodine-125, therapeutic and surgical gels containing isotopes.
Rafarma Pharmaceuticals is actively developing a muon radiography project based on emulsion detectors using artificial intelligence. This is a promising method of studying the internal structure of large natural and industrial facilities which allows, in particular, to monitor the condition of volcanoes, karst caves, mines, nuclear power complex installations, and provide early detection and forecasting of the development of probable emergencies, as well as conducting geological exploration in space.
Rafarma is excited about the cooperation with JINR, whose scientific and experimental facilities are geographically located in the Dubna, the science city of the Moscow region, in the Russian Federation. It is a world-renowned scientific center, which is a unique example of successful integration of theoretical and experimental research with the development and application of the latest technologies along with university academics. JINR's reputation in the world scientific community is very high. The Institute has the only superconducting accelerator of nuclei and heavy ions in both Europe and Asia, with record parameters for conducting experiments on the synthesis of heavy and exotic nuclei, a unique neutron pulse reactor IBR-2 and a proton accelerator and a plastron for proton therapy.
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information contact:
RAFARMA
(307) 429-2029
$RAFA RAFA To Add Major Component to the Tashkent Pharma Park
Press Release | 12/17/2021
Nicosia, Cyprus, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) and the Czech company “Block” signed an agreement on the implementation of the construction of a scientific and pharmaceutical complex in the territory of the Tashkent Pharma Park in Uzbekistan. The new partner of the promising project is the multinational engineering group BLOCK with a unique specialization and experience in the field of healthcare and pharmacology. The interests of Rafarma in this agreement will be represented by the company RAFA Therapeutics Uzbekistan.
In accordance with the agreement, Block will undertake the design of the future complex, including a system of clean laboratory rooms with all the necessary equipment within the framework of the project. The centerpiece will be a project for a plant to produce drugs from human blood plasma with a potential processing capacity of more than 1 million liters of plasma per year and an investment volume of more than US $50 million dollars. Its launch will allow Uzbekistan to become one of the 10 countries in the world with the largest fractionation plants for the processing of blood components.
We plan to complete the design work in April 2022 and begin construction of the first phase of the plant in the summer of 2022.
This latest development is part of Rafarma Pharmaceuticals’ previous announcement to build a scientific and pharmaceutical complex in the territory of the Tashkent Pharma Park by the end of 2026. At the first stage, it is planned to organize the production of cancer drugs and drugs from human donor blood plasma. At the second stage, a complex will be built for the production of drugs based on antibodies (-MABs) and radiopharmaceuticals used for the diagnosis and treatment of various types of cancer. In addition to modern high-tech production lines, the project provides for the creation of a network of laboratories for the collection of blood plasma, the total investment is US $85 million dollars. Experts recognize these construction plans as the largest innovative project of the industrial zone of the Tashkent Pharma Park pharmaceutical cluster.
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information contact:
RAFARMA
(307) 429-2029
Rafa is a joke. Downward trend for 6 months and doesn't seem to want to stop. Barry's 'island' picks are as bad as PRED! Everyone gets burned.
Stock has been in a steady decline for months. NOT a good sign, especially with all the 'good' news coming out.
Is this the beginning to the end for RAFA !!!!!!!!!!!!!!!!!!!!!!!!!!
Hummmmmm,
IB_ ;)
Still have not bought back RAFA as it continues to drop from my previous post
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166604514
I wish RAFA would have a little fake rally so I could short it back down and make a quick buck !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
IB_
$16 Million LoL ..RAFA can run through that in a month !!!!!!!!!!!!!!!
RAFA is pretty close to the yearly low,
No Surprise,
IB_
$16 million cash on hand at end of September per the fillings. 2022 is looking nice baby!
I wonder if RAFA will go bankrupt in 2022 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
It looks bad,
IB_
As RAFA sinks back below a Buck !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Loser Stock,
IB_
$RAFA Explosive Growth Launches Kraspharma Into REMEDIUM TOP-5
Press Release | 11/19/2021
Nicosia, Cyprus, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) reports that PJSC Kraspharma at the end of 2020 entered the TOP-5 of the most dynamic and largest pharmaceutical companies in Russia for 2020, showing incredible growth rates with a net profit increase of 220.9% compared to 2019. Specifically, Kraspharma went from $5,563,056 (USD) at the end of 2019 to $17,853,905 at the end of 2020. The growth was featured in the ratings by the authoritative Russian industry publication "Remedium", published in Q3 of 2021.
(See https://remedium.ru/industry/pharmindustry/analysis/Reyting-predpriyatiy-farmpromyshlennosti-po-obemu-valovoy-pribyli-za-2020-god/)
Remedium's ratings are calculated based on the annual financial statements of 90 companies representing the largest pharmaceutical companies in the country. Remedium’s ratings only include profitable businesses. According to these standards, PJSC Kraspharma entered the top five largest companies in terms of gross profit growth dynamics, outpacing the long-term leaders of this rating by ten times. The company also entered the TOP-30 of the largest pharmaceutical companies in terms of gross profit, retaining its position since 2019.
Also, according to the monthly monitoring of the Russian pharmaceutical market compiled by DSM Group, for the first nine months of 2020 PJSC Kraspharma entered the TOP-5 rating of manufacturers of antibacterial agents for systemic use. During the reporting period, PJSC Kraspharma increased the volume of sold antibiotics by more than 40%. For more details see:
https://cyberleninka.ru/article/n/obzor-prodazh-antibakterialnyh-preparatov-po-itogam-9-mesyatsev-2020-goda/viewer
https://www.kommersant.ru/doc/4626162
https://www.elibrary.ru/title_about_new.asp?id=9038
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information contact:
RAFARMA
(307) 429-2029
$7 million more cash on hand than last year. That’s what matters.
From Stocktwits...
Another misleading tweet from $RAFA
It's Q3YTD and this year Q3 underperformed last year Q3:
$1.4M less revenue,
$1.6M less net income, and
$.02 less EPS. YTD is worse.
Ilya just put his zero growth companies into $RAFA
Can't keep blaming COVID. Its a pharma company after all. Adapt or die.
Otherwise, of course, this is the stock of my life - ugh! LOL.
*RAFA* Company “Rafarma Pharmaceuticals Inc.” Combined Financial statements for the period ended, September 30, 2021
Third Quarter Results
https://www.otcmarkets.com/otcapi/company/financial-report/311676/content
Financial Highlights Q3
$51.3 Million in Sales
$18.2 Million Gross Profits
$7.24 Million Income after Taxes
$0.082c Earnings Per Share
$12.4 Million in Cash
87.7 Million Shares Outstanding [unchanged]
Disclosure Statement Q3
https://www.otcmarkets.com/otcapi/company/financial-report/311675/content
Hopefully RAFA will continue to climb !!!!!!!!!!!!!!!!!!!!!
IB_
I've been trying to average down since I bought in the 2 dollar range so sitting at 1.36 average I'm feeling a little better.
Very nice day for those who bought RAFA yesterday or below a dollar !!!!!!
IB_
Well we know 2020 audits are probably done and 2021 audits will be done in a few months. So yes, why not come out with the 2020 audits and let some hedge funds come in. Make sense to me
Volume and price jump… only 1 day, but I’ll take it. Maybe a form 10 coming?
Major exchanges are absolutely interested in a company with current revenues of $120 million of which will probably double next year.
RAFA is not going on the Nasdaq or the NYSE ........................
Look at the share price and the history of the stock, neither exchange would want this POS on their board,
IB_
They should qualify for both NYSE and Nasdaq once the funds are able to buy. Stay tuned.
Up list to what ?????????????????????????
IB_
Not really that slow. They had to go in person to multiple Rafa owned entities in multiple countries with thousands of different products that had to be auditted and already banged out 2020. And they did that during Covid with small travel windows available. Very impressive.
LJ Soldinger is one of the top international auditors in the world and I’m confident they will get us prepared for uplist as soon.
I have not been short RAFA for almost 2 months !!!!!!!!!!!!!!!!!!!
I actually thought $1.00 might hold but it didn't ........................
It's almost 2022, seems like RAFA has some "slow" auditors,
LoL LoL,
IB_
Great. Stay short then. 2020 audit could drop at any second. Tomorrow? Next week? Tick tick.
Rafarma is a "Coulda, Woulda, Shoulda Stock !!!!!!!!!!!!!!!!!!!!!!!
I might be a buyer at .63,
IB_ ;)
LOL. A company with unlimited money can do buybacks to get the share price wherever they need. I mean they just put $100 million into the Uzbekistan Pharna Park and $9.5 million into Russia operations. Getting the price to $4 after audits should be no problem especially when funds will be able to buy when the audits drop.
So what exchange does Rafarma expect to up list to with a falling share price that's well below a dollar ????????????????????????????????
LoL LoL,
IB_
Pretty good actually. 2020 audit done and 2021 done soon.
How is Rafarma's up listing coming along on this nice red day ?????????
IB_
$RAFA Status Update to Shareholders from Rafarma Pharmaceuticals, Inc.
Press Release | 11/08/2021
Nicosia, Cyprus, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) provides the following update to shareholders:
The company is continuing its PCAOB auditing process, and, after input from accounting, legal and business consultants, is changing the planned auditing years to 2020 and 2021. This decision comes not only because of business factors (e.g., pandemic delays, significant changes in international tax legislation and legislation in the target markets of the company, as well as other several objective factors) but also because the audited information will be more current and will more thoroughly showcase the company’s business strength to the public market. Other than changing audit years, the process will continue and enable Rafarma to apply for uplisting on a major market platform. As always, our goal is to build a well-calibrated business operations and market transparency.
Additionally, we are pleased to announce that R.& D. BIOCOGENCY LABORATORIES INC. LTD will complete a $9.5 million capital infusion to Rafarma by the end of 2021. The cash will be used to finance current costs for consultants, scientific laboratories, contactors, and project organizations, as well as to finance the previously-announced project in Uzbekistan.
In addition, the progress on R&D projects in Turkey and Thailand continues, with further updates to follow.
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information contact:
RAFARMA
(307) 429-2029
Followers
|
97
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6000
|
Created
|
05/17/10
|
Type
|
Free
|
Moderators |
Many OTC stocks are easily overlooked because they don't get the coverage of peers traded on national exchanges and consequently very few investors have the opportunity to know about them. A perfect example is the recent closing of a reverse merger increasing sales by over 700% and adding sizable international operations of private Biocogency into Rafarma Pharmaceuticals (OTC: RAFA) where the RAFA share price has not yet reflected the new added value.
On October 19, 2020, the merger of Biocogency into Rafarma was announced and went unnoticed. Although important metrics to determine share valuations have soared as a result of the merger, the share price has not yet caught up reflecting the new increased valuations simply because nobody knows about it yet. As word is likely to spread soon, the share price is expected to begin climbing to more fair and reasonable market valuations that could exceed expectations.
About Rafarma Pharmaceuticals
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells cannabis health-related products and specialty pharmaceuticals. The company formerly known as Johnston Acquisition Corp. changed its name to Rafarma Pharmaceuticals, Inc. and is based in Sandy, Utah with a manufacturing and distribution facility in Russia.
Biocogency owns PJSC "Krasfarma", the largest Russian chemical and pharmaceutical production company with more than 50 years of experience in the production of drugs that meet all national and international quality standards.
The Company helps meet the growing needs of health care for high-quality, effective and safe generic pharmaceuticals as well as development and production of innovative pharmaceutical products. Production systems with a strong emphasis on safety are carried out through a coordinated interaction of their quality control department, commercial department, logistics service, and scientific information department and pharmacovigilance services.
A rich history is not the most important thing in the modern pharmaceutical industry. To keep the quality of products on a permanently high level, a program of production modernization is being realized: investments in the company include new industrial lines, engineering systems and control systems, as well as new pharmaceutical products.
Safe and effective generic medicines of PJSC "Kraspharma", which are not inferior in clinical efficacy to the original, but sold at affordable prices, have won the trust of both doctors and patients.
Today PJSC "Kraspharma" is the Eastern Europe and Russia undisputed leader in the production of:
Most of the drugs produced are included in Vital and Essential Drugs List (VED) approved by the Government of the Russian Federation.
The products of PJSC "Kraspharma" are sold in Russia, Eastern Europe, Central Asia and in the countries of the Asia-Pacific region.
What Biocogency Adds to Rafarma
This transformative merger starts by restating Rafarma 2019 sales from $11.4 million to $84 million and delivers impressive growth rates of close to 50%.
The Biocogency group includes Russia-based drug companies Bebig and PJSC Kraspharma and industrial firm Slavich. Bebig is focused on developing therapies and diagnostics for cancer care in the Russian markets, including supplying microsources for the treatment of prostate cancer using low-dose brachytherapy. Kraspharma, Russia's largest chemical and pharmaceutical production company (and crown jewel of the merger), and Slavich, a manufacturer of a variety of products including packaging goods, materials for microelectronics and photo materials, are both steeped in corporate history going back half a century or more in Russia.
Biocogency also brings leadership committed to growing value as measured by the fact the deal was structured to be non-dilutive to existing RAFA shareholders. To that point, Ilia Shpurov has assumed the position of Chairman of the Board, bringing decades of entrepreneurial – and biotech – success to RAFA.
What's in it for RAFA? An Immediate Spike in Revenue and Profits
The merger with Biocogency is a game changer for RAFA operations and the top and bottom lines. Consider that in 2019, RAFA generated revenue of approximately $11.4 million and gross profit of $3.4 million. In the latest quarter, ended July 31, 2020, Rafarma reported revenue of $5.3 million and gross profit of $3.1 million, according to filings with OTC Markets Group.
Those results are going to get an immediate shot of adrenaline.
During fiscal 2019, the Biocogency group reported unaudited consolidated earnings of $73 million and gross profits of $17 million. As a course of becoming fully reporting and planning to uplist, the financial results are being audited and adjusted to meet GAAP standards.
Using the results from 2019, it is easy to extrapolate pro forma revenue of $84.4 million and gross profit of $20.3 million for the combined company. It is those type of financials that will underpin a move to the Nasdaq or NYSE.
More on how the price to sales ratio stacks up to industry comps are discussed here. Several Pharmaceutical market comps point to Rafarma share prices that are many multiples higher than the current price of $1.69.
When it comes to value, it certainly bears mentioning the investments that Biocogency has put into its pipeline and platforms since 2012, which management pegs at more than $120.0 million. Much of this investment has been directed by Shpurov since he bought the Kraspharma during the outbreak of the global financial collapse in 2008 for the purpose of restoring and expanding production volumes post-recession while establishing a high-tech GMP pharmaceutical manufacturer in Krasnoyarsk.
That was accomplished. Today, Kraspharma is a leading producer of wide swath of generic drugs and pharma products spanning antibiotics, blood substitutes, infusion solutions, tuberculosis and preparations for other pharmacological groups. Sales channels extend throughout Russia, Eastern Europe and the Asia-Pacific region.
Widening the Footprint
The plan is for vertical growth by expanding the existing channels while leveraging RAFA relationships for horizontal growth through entering the lucrative North American markets.
In fairness, Russia alone can be a company maker. A huge net importer of medicine, the Russian government is pushing for national security in the supply chain as outlined in the Pharma 2030 Strategy. With that in mind, Statista forecasts the Russian pharmaceutical industry will grow 147% between 2017 and 2030.
During Q1, the Russian pharma market surged 125% year-over-year to about 320 billion Russian rubles (US$4.2 billion). Generic drugs typically dominate the prescription market, accounting for 64.5% of the category in 2017, meaning Kraspharma is in a strong position.
Given the sheer volume of people, Asia is another tremendous market. The Rx market in China alone is forecast to reach $160 billion by 2022, highlighting the market opportunity. With respect to the Asian drug development market, ResearchAndMarkets estimates 6.54% compound annual growth to reach $62.46 billion by 2026.
Still, the U.S. is the Holy Grail as the biggest pharmaceutical market in the world, weighing in at a whopping $484.4 billion in 2018.
Conclusion
With the reverse merger now closed, the newly created Rafarma Pharmaceuticals that now boasts fast-growing operations well in excess of $100 million for 2019 is decidedly undervalued when compared to industry valuations for similar companies. Management plans for uplisting and higher investor awareness programs are soon in the future which will help bring the Rafarma opportunity to the forefront resulting in substantially higher prices and trading volume.
The current price has not yet appreciated to reflect the newly increased sales and valuations and therefore presents an opportunity to astute investors who act now before the story becomes more commonly known.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |